Context End Period Cash Flow from 2010 to 2025

CNTX Stock  USD 1.01  0.03  3.06%   
Context Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2025. During the period from 2010 to 2025, Context Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.35 and arithmetic mean of  9,028,719. View All Fundamentals
 
End Period Cash Flow  
First Reported
2018-09-30
Previous Quarter
101.5 M
Current Value
84.8 M
Quarterly Volatility
29.3 M
 
Covid
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.44. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Context Therapeutics Correlation against competitors.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Context Therapeutics over the last few years. It is Context Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Context End Period Cash Flow Regression Statistics

Arithmetic Mean9,028,719
Geometric Mean2,202,574
Coefficient Of Variation163.39
Mean Deviation11,209,912
Median1,105,296
Standard Deviation14,751,978
Sample Variance217.6T
Range49.5M
R-Value0.59
Mean Square Error150.7T
R-Squared0.35
Significance0.02
Slope1,842,225
Total Sum of Squares3264.3T

Context End Period Cash Flow History

202518.6 M
202416.6 M
202314.4 M
202235.5 M
202149.7 M
2020341 K

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow16.6 M18.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.